Aggregation of a biotherapeutic is of significant concern and judicious process and
formulation development is required to minimize aggregate levels in the final product …

Potential aggregation prone regions in biotherapeutics | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …

Abbreviations: mAb, monoclonal antibody; FDA, food and drug administration; CDR,
complementarity determining region; Fab, fragment, antigen binding; Fc, fragment …

Aggregation of a biotherapeutic is of significant concern and judicious process and
formulation development is required to minimize aggregate levels in the final product …

Aggregation of a biotherapeutic is of significant concern and judicious process and
formulation development is required to minimize aggregate levels in the final product …

Aggregation of a biotherapeutic is of significant concern and judicious process and
formulation development is required to minimize aggregate levels in the final product …

Abbreviations: mAb, monoclonal antibody; FDA, food and drug administration; CDR,
complementarity determining region; Fab, fragment, antigen binding; Fc, fragment …

Aggregation of a biotherapeutic is of significant concern and judicious process and
formulation development is required to minimize aggregate levels in the final product …